After years of stagnant share performance, CVS Health（CVS）has staged a notable turnaround. As of the market close on May 25, the U.S. healthcare giant’s stock has surged more than 107% since the start of 2025. Long viewed as a reliable dividend play, the company now sees its share price and dividend strength moving in tandem, drawing widespread market attention to the core drivers behind its solid performance.
Strong operating cash flow has long secured CVS’s attractive dividend program. The firm’s current dividend yield stands at nearly 2.9%, more than 2.5 times the average yield of the S&P 500 Index. In the first quarter ending March 31, CVS generated $4.2 billion in operating cash flow. Although the figure edged down from $4.6 billion a year earlier, it remains ample to cover dividend obligations. The company paid out $847 million in dividends during the quarter, which accounted for just over 20% of its quarterly operating cash flow.
Looking ahead to the full year, CVS projects operating cash flow of at least $9.5 billion, compared with an estimated annual dividend payout of $3.39 billion, leaving a comfortable buffer for sustained distributions. To pay down debt stemming from its acquisition of Aetna, CVS paused annual dividend increases for nearly four years and has kept this policy in place today. Even with elevated debt levels at present, investors face little risk of a dividend cut thanks to consistent cash generation. Over recent years, its annual operating cash flow has consistently ranged between $9 billion and $10.5 billion, and its current dividend yield of around 2.8% still holds strong appeal for income-focused investors.
A broad-based recovery across business segments is the key catalyst fueling the stock’s sharp rally. CVS delivered first-quarter financial results that handily topped analyst estimates. Total revenue reached $100.4 billion, rising 6.2% year over year, while earnings per share climbed 62% to $2.30. The upbeat quarterly performance prompted the company to raise its full-year earnings and cash flow guidance, signaling a clear improvement in operational momentum.
CVS has built a vertically integrated healthcare ecosystem covering pharmacy services, health insurance and pharmacy benefit management, creating a durable competitive edge that peers struggle to replicate. All three core business divisions posted revenue growth in the first quarter. The Health Benefits segment, home to Aetna, recorded $35.9 billion in revenue, up 3.3% year over year. Its medical benefit ratio dropped notably from 87.3% to 84.6%, easing cost pressures from medical claims. CVS also plans to exit its unprofitable individual health insurance exchange business in 2026, a strategic move set to further lift profitability within its insurance arm. The Pharmacy and Consumer Wellness segment saw modest revenue growth, supported by higher prescription volumes amid ongoing store closures of rival retailers. The Health Services segment turned in the strongest performance, with revenue hitting $48.2 billion, an 11% year-on-year increase.
While fundamentals keep improving, heavy debt remains a lingering headwind for CVS. As of the end of the first quarter, the company’s long-term debt totaled $86.4 billion. Substantial interest expenses divert capital that could otherwise be deployed for business expansion and share repurchases. Nevertheless, the company is making steady progress in deleveraging: its overall debt fell 1.5% year over year to $175 billion.
Market analysts have assigned an average price target of $101.58 to CVS stock. With its robust cash flow, steady dividends and rebounding core businesses, the stock still has room for further upside.
